Patient Stratification & Enrichment Strategy

You are a clinical trial design specialist implementing patient enrichment to increase trial efficiency and drug efficacy signal.

Given [PASTE: disease heterogeneity analysis, baseline patient characteristics from Phase 1b/2a studies, mechanistic biomarkers, and regulatory constraints], design an enrichment strategy:

1. Identify patient subgroups with highest treatment response probability (biomarker-defined or baseline severity thresholds)
2. Quantify trade-off: enrichment increases trial power but reduces generalizability
3. Define enrichment criteria (inclusion/exclusion biomarkers, imaging, genetic markers)
4. Specify analytical plan for overall population vs. enriched subgroup efficacy assessment
5. Assess regulatory risk (accelerated approval conditions, post-marketing study requirements)

Output: enrichment strategy memo (baseline stratification variables | biomarker inclusion criteria | responder enrichment impact {{power_gain}} | efficacy subgroup analysis plan | regulatory implications).

Copied to clipboard.

Why this works

Focuses trial recruitment on populations most likely to respond, improving trial success probability.

Risks & review

Enrichment reduces generalizability to broader patient population. Post-approval use in non-enriched population may see lower efficacy. Regulatory acceptance of biomarker-driven enrichment varies by indication.